Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 – 2032

Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 – 2032

The global tardive dyskinesia therapeutics market size is expected to reach USD 5.57 billion by 2032, according to a new study by Polaris Market Research. The report “Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The drastic increase in the prevalence of various neurological and psychotic disorders and growing need for disease-specific novel treatment, are the leading factors propelling market’s growth. Additionally, increase in financial support to the researchers and health institutes for advancing the novel intervention and bring innovations in the healthcare sector including therapeutics for tardive dyskinesia, are further anticipated to drive market’s growth.

• For instance, in November 2023, Neurocrine Biosciences, introduced DISCOVER TD, which is an interactive digital tool specially designed to help healthcare providers learn and identify about the tardive dyskinesia. Tool is built in collaboration with the clinical experts.

The rising cases of mental illnesses across the globe which requires prolonged treatment with antipsychotic drugs that causes irregular dopamine, fostering the demand for effective therapeutics. Also, the growing adoption of neuropsychological testing for monitoring or detecting changes in cognitive function, identifying specific patterns, and speed of information processing, are also propelling the market’s growth. For instance, as per a report by the Centers for Disease Control and Prevention, nearly 1 in 5 US adults live with some form of mental illness, & nearly1 in 5 youth have seriously debilitating mental illness during their life.

Furthermore, the guideline of the American Academy of Neurology was updated recently for incorporating 2 FDA-approved VMAT2 inhibitors including valbenazine & deutetrabenazine, which has been marked as a huge milestone because they had undergone multi-center, randomized, & double-blind clinical trials. They were the first one which is going to be supported by the level A evidence and were mainly approved for the treatment of tardive dyskinesia in the United States.

Tardive Dyskinesia Therapeutics Market Report Highlights

• Valbenazine segment accounted for the noteworthy share, on account of rising number of awareness campaigns about such diseases and their therapeutics
• Solid dosage form segment held the majority share, driven by its rising adoption by healthcare professionals and higher effectiveness of medication
• Online pharmacies segment will grow at highest pace, due to rising number of online buyers and emergence of several online pharmacies for the remotest places
• North America dominated the global market, owing to region’s greater awareness about disease and wider availability of treatment options, coupled with positive reimbursement scenario
• The key market players include Reddy Laboratories, SOM Biotech, Luye Pharma Group, Prestwick Pharmaceuticals, Sun Pharmaceuticals Industries, and Allergan

Polaris Market Research has segmented the tardive dyskinesia therapeutics market report based on drug, product type, distribution channel, and region:

Tardive Dyskinesia Therapeutics, Drug Outlook (Revenue - USD Billion, 2019 - 2032)

• Deutetrabenazine
• Valbenazine
• Others

Tardive Dyskinesia Therapeutics, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Solid Dosage Forms
• Tablets
• Capsules
• Liquid Dosage Form
• Injection

Tardive Dyskinesia Therapeutics, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Others

Tardive Dyskinesia Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

- U.S.

- Canada

• Europe

- Germany

- UK

- France

- Italy

- Spain

- Russia

- Netherlands

• Asia Pacific

- China

- India

- Japan

- South Korea

- Indonesia

- Malaysia

• Latin America

Argentina

Brazil

- Mexico

• Middle East & Africa

- UAE

- Saudi Arabia

- Israel

- South Africa